{"id":351,"date":"2026-06-03T08:03:00","date_gmt":"2026-06-03T08:03:00","guid":{"rendered":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/"},"modified":"2026-06-04T18:43:48","modified_gmt":"2026-06-04T18:43:48","slug":"surge-in-mas-driven-by-patent-expirations","status":"publish","type":"post","link":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/","title":{"rendered":"Impending patent cliffs drive surge in acquisitions"},"content":{"rendered":"


\n<\/p>\n

\n

Life science corporations\u00a0usually forge\u00a0mergers and acquisition (M&A)\u00a0offers\u00a0to\u00a0get rid of\u00a0competitors\u00a0or to develop a pipeline. Not too long ago, there was a spike in M&As, however\u00a0analysts\u00a0level in the direction of imminent patent cliffs because the trigger. We have a look at how M&A curiosity impacts\u00a0revenues and market exclusivity within the healthcare business.\u00a0<\/p>\n

M&A exercise within the healthcare and life sciences sectors has been burgeoning.\u00a0A\u00a0report\u00a0by\u00a0EY\u00a0indicated\u00a0an 81% bounce\u00a0in M&A investments\u00a0final yr from 2024, hitting $240 billion.\u00a0Figures from the primary quarter of this yr recommend that\u00a0M&As are\u00a0holding\u00a0regular at 130\u00a0offers,\u00a0however\u00a0in comparison with the $106.8 billion that the ultimate quarter of 2025 raked in, it fell to $82.7 billion.\u00a0<\/p>\n

Yale Jen, healthcare fairness Analyst and Managing Director at Laidlaw & Firm,\u00a0attributes\u00a0this surge in buyouts to 2 components.\u00a0<\/p>\n

\u201cOne is that biotech valuation continues to be in an affordable if not at an overvalued stage. This makes the M&A extra reasonably priced,\u201d stated Jen, who added that many corporations have a \u201cvery wholesome steadiness sheet\u201d,\u00a0which makes M&A way more manageable.\u00a0<\/p>\n

Acquisition premiums fall;\u00a0file excessive M&As in current occasions\u00a0<\/h2>\n

Certainly, acquisition premiums have dropped by 40% in 2025, contemplating\u00a0these takeover quantities that exceeded valuation numbers had been fairly excessive between 2020 and 2024. This displays a \u201cextra disciplined method to worth creation,\u201d based on\u00a0a report by McKinsey and Firm. The report\u00a0revealed\u00a0that consumers are prioritizing\u00a0long-term pipeline renewal and platform\u00a0over transactions that\u00a0yield\u00a0mere\u00a0short-term income\u00a0highs.\u00a0<\/p>\n

As an illustration, in a area like medtech, the previous yr noticed buying and selling on the lowest valuations since\u00a0the\u00a02008\u00a0monetary disaster. This led\u00a0administration groups at life science corporations to rethink how they\u00a0handle their portfolios, spurring M&As, which\u00a0hit its peak since 2021.\u00a0\u00a0<\/p>\n

This was\u00a0largely owed\u00a0to\u00a0macro\u00a0components akin to\u00a0rising rates of interest and tighter financial insurance policies in addition to\u00a0what\u2019s\u00a0come to be often called a post-COVID market correction following\u00a0the business\u2019s growth with file funding\u00a0from 2020 to 2022.\u00a0Furthermore, the valuation hole in synthetic intelligence (AI) has develop into extra\u00a0obvious. Now, consumers\u00a0in\u00a0the\u00a0life science and healthcare\u00a0sector\u00a0are pivoting in the direction of\u00a0corporations which have included AI.\u00a0Some that\u00a0haven\u2019t\u00a0achieved so\u00a0have suffered decrease exit multiples.\u00a0\u00a0<\/p>\n

All this has laid the groundwork for giant pharma to\u00a0purchase\u00a0distressed property at a time when patent cliffs are\u00a0looming. Jen defined that that is the opposite\u00a0motive why\u00a0M&As have been\u00a0elevated; \u201cthe necessity for managing the longer term patent cliff for among the main pharma and wish extra worth drivers for a lot of giant biotech corporations,\u201d he identified.\u00a0<\/p>\n

\u201cSome banks have urged that 2026 probably might be the second most energetic yr of M&A in current time,\u201d\u00a0he\u00a0stated.\u00a0<\/p>\n

\n
\n
\n

Though M&A has at all times be one of many main exits for biotech buyers, the current elevated actions definitely additional increase this pattern. Firms growing late or early scientific stage merchandise each might\u00a0profit\u00a0from this. For late scientific or early industrial stage names,\u00a0it’s clear that acquirers\u00a0must complement the wants of their present commercialized illness franchise<\/p>\n

Yale Jen, healthcare fairness Analyst and Managing Director at Laidlaw & Firm<\/p><\/blockquote>\n<\/div>\n<\/div>\n

The final time M&As spiked was again in 2019, when the business recorded an\u00a0estimated\u00a0$328 billion in deal worth, purely from M&As.\u00a0The\u00a0blockbuster yr\u00a0witnessed\u00a0greater than 480 offers, pushed by buyouts of late-stage pipelines\u00a0to guard in opposition to patents expiring on the time, a giant one being\u00a0AbbVie\u2019s\u00a0monoclonal antibody Humira for treating inflammatory situations, whose patent resulted in 2023. So, AbbVie purchased\u00a0Irish pharmaceutical and\u00a0Botox developer Allergan\u00a0for $63 billion in 2019.\u00a0<\/p>\n

Unsurprisingly, historical past\u00a0appears to have\u00a0repeated\u00a0itself.\u00a0\u00a0<\/p>\n

When patents expire, it permits for cheaper generics to enter the market.\u00a0Within the face of impending generic competitors and\u00a0in an effort to\u00a0exchange billions in income\u00a0losses, pharma giants are\u00a0buying\u00a0promising\u00a0biotechs.\u00a0<\/p>\n

What do patent cliffs need to do with it?\u00a0<\/h2>\n

An EY\u00a0report\u00a0revealed that within the subsequent few years, huge\u00a0pharmas\u00a0are anticipated\u00a0to\u00a0lose greater than $350\u00a0billion in income, significantly from blockbusters which have to date loved market exclusivity.\u00a0\u00a0<\/p>\n

Take for example,\u00a0Merck\u2019s\u00a0$6.7 billion buyout of Terns Prescribed drugs. The massive pharma firm presently faces the approaching lack of market exclusivity for its\u00a0most cancers drug Keytruda. The monoclonal antibody was greenlit by the U.S. Meals and Drug Administration (FDA) to deal with melanoma in 2014.\u00a0Solely two years later, it grew to become a blockbuster, surpassing a billion {dollars}\u00a0in income, and has been authorized to deal with greater than 40 most cancers varieties since.\u00a0\u00a0<\/p>\n

As Merck\u2019s patent for the antibody pembrolizumab, the energetic ingredient in Keytruda,\u00a0expires in the direction of the tip of 2028, it purchased Terns, which develops small molecules for most cancers and weight problems, in March. The enormous clocked the potential of TERN\u2011701, the latter\u2019s tyrosine kinase inhibitor\u00a0in treating continual myeloid\u00a0leukemia, a sort of blood most cancers.\u00a0<\/p>\n

This was following the American pharmaceutical\u2019s $10 billion buy of Verona Pharma late final yr.\u00a0Additionally geared toward plugging the income hole that Keytruda is about to go away, Merck set its sights on\u00a0Verona\u2019s\u00a0Ohtuvayre, a small molecule\u00a0indicated\u00a0for the upkeep remedy of continual obstructive pulmonary illness (COPD) in adults authorized by the FDA in 2024.\u00a0\u00a0<\/p>\n

Pfizer\u2019s acquisition of\u00a0Metsera\u00a0protects revenues\u00a0<\/h2>\n

In addition to Merck, Pfizer\u00a0acquired\u00a0metabolic disease-focused\u00a0Metsera\u00a0for\u00a0as much as $10 billion\u00a0in November. Pfizer simply misplaced the patent to Eliquis, a blood thinner for stopping blood clots.\u00a0Subsequent yr, will probably be stripped off its patent rights to 2 of its small molecule most cancers medicine, each blockbusters:\u00a0Ibrance\u00a0is a CDK4\/6 inhibitor for treating breast most cancers and Xtandi is a hormonal remedy for prostate most cancers.\u00a0<\/p>\n

The\u00a0Metsera\u00a0buy\u00a0was a giant deal, contemplating\u00a0Pfizer\u00a0needed to combat\u00a0off\u00a0Novo Nordisk, which supplied $6.5 billion upfront \u2013 greater than Pfizer\u2019s\u00a0preliminary\u00a0$4.9 billion upfront provide. Novo, nonetheless,\u00a0encountered\u00a0pushback from antitrust regulators,\u00a0because it had a monopoly\u00a0in\u00a0\u00a0the\u00a0GLP-1\u00a0area \u2013 being the developer of famed weight reduction medicine Ozempic\/Wegovy \u2013\u00a0and\u00a0Metsera\u00a0was constructing its personal GLP-1 pipeline. It\u00a0in the end misplaced\u00a0the bidding conflict in opposition to Pfizer when Metsera\u00a0went with\u00a0the latter.\u00a0<\/p>\n

Novo\u00a0itself simply misplaced the patent to semaglutide, the energetic ingredient in Ozempic and Wegovy in nations like\u00a0Canada and India this yr, the latter being a fast-growing hub for generics.\u00a0However\u00a0it ready to offset this by\u00a0constructing a patent thicket, having filed lots of of follow-on patents.\u00a0It additionally\u00a0licensed\u00a0United Laboratories\u2019\u00a0UBT251\u00a0for $5.2\u00a0billion from California-based Akero Therapeutics\u00a0final yr. The candidate is a triple-agonist drug that targets three hormonal pathways, GLP-1, GIP, and glucagon, to probably be simpler than semaglutide.\u00a0<\/p>\n

In the meantime,\u00a0Bristol Myers Squibb, Johnson & Johnson, and AbbVie,\u00a0and Regeneron\u00a0are all coping with patent expirations.\u00a0Regeneron\u00a0developed Eylea, which was authorized by the FDA in 2011.\u00a0The fusion protein is injected into the attention to deal with\u00a0situations\u00a0like\u00a0moist age-related macular degeneration that trigger imaginative and prescient\u00a0loss. Regeneron sells it within the U.S. whereas Bayer sells it in all places else.\u00a0In addition to,\u00a0Regeneron and Sanofi\u00a0are set to lose the patent of their\u00a0monoclonal antibody Dupixent\u00a0for inflammatory situations\u00a0in 5 years\u2019 time.\u00a0With Eylea,\u00a0it seems prefer it\u00a0has been propped\u00a0itself\u00a0up with a patent thicket, as\u00a0greater than 130 purposes been filed and 91 authorized.\u00a0As for Dupixent, we must see what the pharma big\u00a0comes up with\u00a0to delay the entry of generics.\u00a0<\/p>\n

M&As: Johnson & Johnson and Novartis circumvent losses from patent expirations\u00a0<\/h2>\n

Johnson & Johnson has a number of medicine in the marketplace that\u00a0are on the point of dropping patents, akin to\u00a0Stelara\u00a0and\u00a0the\u00a0AbbVie-co-owned\u00a0Imbruvica.\u00a0Stelara is a monoclonal antibody for\u00a0inflammatory and autoimmune situations\u00a0and\u00a0has\u00a0had patents expire over the previous few years and in 2026, as biosimilars swarm the market.\u00a0Imbruvica, a tyrosine kinase inhibitor for blood most cancers, will\u00a0lose patents this yr and the following, however\u00a0earnings will stay\u00a0largely\u00a0untouched\u00a0out there\u00a0due to authorized settlements blocking the launch of generics till 2032.\u00a0\u00a0<\/p>\n

Nonetheless, the pharma big indulged in M&As final yr, a $14.6 billion\u00a0buyout\u00a0of Intra-Mobile Therapies and the\u00a0$3.05 billion\u00a0acquisition\u00a0of Halda Therapeutics.\u00a0Intra-Mobile\u2019s\u00a0small molecule\u00a0Caplyta\u00a0is the primary and solely FDA-approved remedy for bipolar\u00a0melancholy as an adjunctive remedy and monotherapy and\u00a0Halda Therapeutics\u2019\u00a0RIPTACs\u00a0look to be a promising molecular glue know-how to kill most cancers\u00a0\u2013 each\u00a0favoring\u00a0J&J\u2019s portfolio.\u00a0<\/p>\n

So as to add to that, Novartis\u2019 Avidity buyout final yr got here as the large pharma\u2019s top-selling coronary heart failure remedy Entresto and bronchial asthma drug Xolair\u00a0misplaced market exclusivity too.\u00a0<\/p>\n

Jen believes that\u00a0patent\u00a0expiration\u00a0for income cliff throughout the subsequent decade is driving main\u00a0pharmas\u00a0to \u201cpull the M&A set off.\u201d He thinks that purchasing up early- and late-stage corporations\u00a0advantages\u00a0huge\u00a0pharmas.\u00a0<\/p>\n

\u201cThough M&A has at all times be one of many main exits for biotech buyers, the current elevated actions definitely additional increase this pattern. Firms growing late or early scientific stage merchandise each might\u00a0profit\u00a0from this. For late scientific or early industrial stage names,\u00a0it’s clear that acquirers\u00a0must complement the wants of their present commercialized illness franchise. The sooner stage packages\u00a0primarily to\u00a0enrich or complement their future pipeline wants,\u201d he stated.\u00a0\u201cGiven the valuation of an M&A occasion at all times contains some M&A premium, many buyers have been properly rewarded\u00a0in current days.\u201d\u00a0<\/p>\n

Whereas some construct patent thickets surrounding their medicine to maintain generics at bay, most huge\u00a0pharmas\u00a0have resorted to M&As\u00a0to exchange as soon as commercially profitable medicine\u00a0with new ones, with the hopes that they may deliver them\u00a0related if no more income. Whether or not chasing\u00a0the shiny new factor is the most effective wager, we must be careful for.\u00a0<\/p>\n<\/div>\n


\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Life science corporations\u00a0usually forge\u00a0mergers and acquisition (M&A)\u00a0offers\u00a0to\u00a0get rid of\u00a0competitors\u00a0or to develop a pipeline. Not too long ago, there was a spike in M&As, however\u00a0analysts\u00a0level in the direction of imminent patent cliffs because the trigger. We have a look at how M&A curiosity impacts\u00a0revenues and market exclusivity within the healthcare business.\u00a0 M&A exercise within the healthcare […]<\/p>\n","protected":false},"author":1,"featured_media":355,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[569,566,567,564,565,568],"class_list":["post-351","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-acquisitions","tag-cliffs","tag-drive","tag-impending","tag-patent","tag-surge"],"yoast_head":"\nImpending patent cliffs drive surge in acquisitions - Future News 24<\/title>\n<meta name=\"description\" content=\"We look at how a surge in acquisitions in the life science industry are being driven by imminent patent cliffs.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impending patent cliffs drive surge in acquisitions - Future News 24\" \/>\n<meta property=\"og:description\" content=\"We look at how a surge in acquisitions in the life science industry are being driven by imminent patent cliffs.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T08:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T18:43:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Impending patent cliffs drive surge in acquisitions\",\"datePublished\":\"2026-06-03T08:03:00+00:00\",\"dateModified\":\"2026-06-04T18:43:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/\"},\"wordCount\":1703,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/patent-cliff-acquisition.jpg\",\"keywords\":[\"acquisitions\",\"cliffs\",\"drive\",\"Impending\",\"patent\",\"surge\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/\",\"name\":\"Impending patent cliffs drive surge in acquisitions - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/patent-cliff-acquisition.jpg\",\"datePublished\":\"2026-06-03T08:03:00+00:00\",\"dateModified\":\"2026-06-04T18:43:48+00:00\",\"description\":\"We look at how a surge in acquisitions in the life science industry are being driven by imminent patent cliffs.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/patent-cliff-acquisition.jpg\",\"contentUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/patent-cliff-acquisition.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/03\\\/surge-in-mas-driven-by-patent-expirations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impending patent cliffs drive surge in acquisitions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impending patent cliffs drive surge in acquisitions - Future News 24","description":"We look at how a surge in acquisitions in the life science industry are being driven by imminent patent cliffs.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/","og_locale":"en_US","og_type":"article","og_title":"Impending patent cliffs drive surge in acquisitions - Future News 24","og_description":"We look at how a surge in acquisitions in the life science industry are being driven by imminent patent cliffs.\u00a0","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/","og_site_name":"Future News 24","article_published_time":"2026-06-03T08:03:00+00:00","article_modified_time":"2026-06-04T18:43:48+00:00","og_image":[{"url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Impending patent cliffs drive surge in acquisitions","datePublished":"2026-06-03T08:03:00+00:00","dateModified":"2026-06-04T18:43:48+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/"},"wordCount":1703,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg","keywords":["acquisitions","cliffs","drive","Impending","patent","surge"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/","name":"Impending patent cliffs drive surge in acquisitions - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg","datePublished":"2026-06-03T08:03:00+00:00","dateModified":"2026-06-04T18:43:48+00:00","description":"We look at how a surge in acquisitions in the life science industry are being driven by imminent patent cliffs.\u00a0","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#primaryimage","url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg","contentUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/06\/patent-cliff-acquisition.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/03\/surge-in-mas-driven-by-patent-expirations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Impending patent cliffs drive surge in acquisitions"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=351"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/351\/revisions"}],"predecessor-version":[{"id":354,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/351\/revisions\/354"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/355"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}